Form 4: Kura Oncology Executive Sells Shares to Cover Taxes

Brian T. Powl, Chief Commercial Officer of Kura Oncology, sold 1,583 shares of common stock to cover taxes related to a vesting of restricted stock units.

Summary

• Brian T. Powl, the Chief Commercial Officer of Kura Oncology, sold 1,583 shares of the company's common stock on January 28, 2025.
• The sale was executed at a price of $7.8719 per share.
• This transaction was a sell-to-cover for taxes associated with the vesting of a restricted stock unit (RSU) that Mr. Powl received on January 2, 2024.
• Following the transaction, Mr. Powl directly owns 59,667 shares of Kura Oncology common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any positive or negative sentiment about the company's performance or future prospects.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Sell-to-cover transactions are a standard practice among publicly traded companies, particularly in the biotech sector where stock options and RSUs are common forms of compensation.
• Similar transactions are regularly reported by executives at comparable companies such as Mirati Therapeutics, Deciphera Pharmaceuticals, and Blueprint Medicines.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale by an executive to cover tax obligations.

Key Dates

Keywords

Kura Oncology, Brian T. Powl, stock sale, insider trading, Form 4, restricted stock unit, RSU, executive compensation